Pacer Advisors Inc. bought a new position in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) during the second quarter, Holdings Channel.com reports. The fund bought 39,796 shares of the company’s stock, valued at approximately $1,397,000.
A number of other hedge funds also recently modified their holdings of RHHBY. Parametric Portfolio Associates LLC lifted its position in shares of Roche Holdings AG Basel by 4.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 5,407,314 shares of the company’s stock worth $185,958,000 after purchasing an additional 217,308 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Roche Holdings AG Basel in the 1st quarter worth approximately $144,000. Diversified Trust Co lifted its position in Roche Holdings AG Basel by 14.2% during the first quarter. Diversified Trust Co now owns 48,165 shares of the company’s stock valued at $1,659,000 after acquiring an additional 6,000 shares during the last quarter. Douglass Winthrop Advisors LLC lifted its position in Roche Holdings AG Basel by 9.2% during the second quarter. Douglass Winthrop Advisors LLC now owns 637,978 shares of the company’s stock valued at $22,393,000 after acquiring an additional 53,702 shares during the last quarter. Finally, Scout Investments Inc. lifted its position in Roche Holdings AG Basel by 15.9% during the second quarter. Scout Investments Inc. now owns 103,699 shares of the company’s stock valued at $3,651,000 after acquiring an additional 14,204 shares during the last quarter. Institutional investors and hedge funds own 0.31% of the company’s stock.
Roche Holdings AG Basel stock traded up $0.71 during mid-day trading on Friday, reaching $34.62. 423,201 shares of the company traded hands, compared to its average volume of 816,434. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.40 and a quick ratio of 1.11. Roche Holdings AG Basel ADR has a fifty-two week low of $28.74 and a fifty-two week high of $35.90. The company has a market capitalization of $237.09 billion, a price-to-earnings ratio of 14.92, a price-to-earnings-growth ratio of 2.22 and a beta of 0.48. The firm’s fifty day moving average is $34.33 and its two-hundred day moving average is $33.98.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Read More: What is the Coverage Ratio?
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.